CFM
TARS icon

Capricorn Fund Managers’s Tarsus Pharmaceuticals TARS Stock Holding History

Capricorn Fund Managers’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,000
Closed -$1.82M – 210
2026
Q1 		$1.82M Buy
26,000
+4,018
+18% +$281K 0.28% 77
2025
Q4 		$1.8M Sell
21,982
-218,038
-91% -$16.3M 0.43% 58
2025
Q3 		$14.3M Buy
+240,020
New +$11.8M 4.79% 2

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Capricorn Fund Managers's TARS Position: Q2 2026 in Review

Capricorn Fund Managers sold out of Tarsus Pharmaceuticals (TARS) in Q2 2026, closing a stake of 26,000 shares — an estimated $1.82M sold.

Capricorn Fund Managers first reported a position in TARS in Q3 2025 and held it in 3 quarters. The position peaked at $14.3M in Q3 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Capricorn Fund Managers reported no remaining Tarsus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Capricorn Fund Managers sold 26,000 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $1.82M.
  • Capricorn Fund Managers first reported a position in Tarsus Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Capricorn Fund Managers's Tarsus Pharmaceuticals position peaked at $14.3M in Q3 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Capricorn Fund Managers's 13F filing for Q2 2026, filed 24 Jul 2026.